Literature DB >> 6401852

Response of a mucinous ovarian tumor of borderline malignancy to human chorionic gonadotropin.

M A Quinn, H W Baker, R Rome, D Fortune, J B Brown.   

Abstract

Plasma and urinary steroid hormones were measured before and after an injection of human chorionic gonadotropin (hCG) to a postmenopausal woman with a mucinous ovarian tumor of borderline malignancy. Hormones were also measured in blood from a vein draining the tumor, and circulating gonadotropins and plasma and urinary steroids were measured before and after tumor removal. Baseline levels of plasma progesterone (P), androstenedione (delta 4 A), and estradiol (E2), and urinary estrogens and pregnanediol were high; they increased dramatically in response to hCG and fell after tumor removal. A less striking increase in testosterone, dihydrotestosterone, dehydroepiandrosterone (DHEA), and DHEA sulfate was noted after hCG injection. A gradient existed between tumor vein and peripheral vein levels of P, 17 alpha-hydroxyprogesterone, delta 4 A, E2, DHEA, and cortisol. Plasma follicle-stimulating and luteinizing hormones initially low but rose to the postmenopausal range after surgery. These results indicate the presence of delta 4 and delta 5 androstene pathways within the tumor. The responsiveness of the tumor to hCG provides further evidence that hCG may be the endogenous stimulus to steroid hormone production by epithelial ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401852

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  A case of mucinous cystadenocarcinoma of the ovary associated with virilization: pre and post-operative steroid plasma levels.

Authors:  D Mango; P Scirpa; F Battaglia; S Sentinelli; E Menini
Journal:  J Endocrinol Invest       Date:  1985-08       Impact factor: 4.256

2.  Virilization of a postmenopausal woman by a mucinous cystoadenoma.

Authors:  Sara Alonso Díaz; Belén Vega Piñero; Lía Nattero Chávez; Ignacio Pinilla Pagnon; Andrés Ortiz-Flores; Manuel Luque-Ramírez
Journal:  Oxf Med Case Reports       Date:  2018-01-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.